Inactive Instrument

Clal Biotechnology Industries Ltd. Stock TEL AVIV STOCK EXCHANGE

Equities

CBI

IL0011042806

Investment Holding Companies

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 370K 100K 136K Sales 2023 104K 28.17K 38.33K Capitalization 62.27M 16.87M 22.95M
Net income 2022 -61M -16.52M -22.48M Net income 2023 -31M -8.4M -11.43M EV / Sales 2022 331 x
Net Debt 2022 23.85M 6.46M 8.79M Net Debt 2023 22.4M 6.07M 8.26M EV / Sales 2023 814 x
P/E ratio 2022
-1.6 x
P/E ratio 2023
-2.01 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 34.65%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 51 15-06-30
Director of Finance/CFO 46 -
Chief Tech/Sci/R&D Officer 55 21-12-31
Members of the board TitleAgeSince
Chairman 67 03-05-08
Director/Board Member 71 15-11-17
Director/Board Member 73 20-02-16
More insiders
Clal Biotechnology Industries Ltd (CBI) is an Israel-based biotechnology investment company. CBI's investments are targeted at bio-pharmaceutical companies, which are at different stages of research and development. The Company is a 59%-owned subsidiary of Clal Industries and Investments Ltd. (CII) that is part of IDB group. Clal Biotechnology Industries Ltd. has a number of portfolio companies, namely Andromeda Biotech Ltd., engaged in the field of type 1 diabetes; D-Pharm Ltd and Trombutech, engaged in the field of ischemic stroke; Mediwound Ltd., engaged in burn and wound management; Biokine Ltd, Biocancell Ltd and CureTech, engaged in the field of cancer; Braintact, engaged in the CNS field and Polyheal Ltd, engaged in wound management, among others.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW